|
Synonyms: REGN-10933 | Ronapreve® (imdevimab + casirivimab)
casirivimab is an approved drug (Japan, EMA and UK MHRA (2021))
Compound class:
Antibody
Comment: Casirivimab (REGN10933) is a fully human monoclonal antibody against the surface spike protein of SARS-CoV-2 [1-2]. It is a virus neutralising mAb that was developed by Regeneron.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use  |
| Evaluated as a cocktail (REGN-COV2) with REGN10987 (imdevimab) for COVID-19. Phase 3 as of November 2020. These two mAbs have non-overlapping epitopes on the SARS-CoV-2 spike protein. In late November 2020 the FDA granted REGN-COV2 emergency use authorization (EUA) for the treatment of mild to moderate COVID-19 in adults and pediatric patients who have had a positive test result and who are in a recognised group at high risk of progressing to severe disease. This EUA does not authorise REGN-COV2 use in hospitalised COVID-19 patients, or in those already receiving oxygen therapy for COVID-19. The EUA was granted, based on data coming from clinical trial NCT04617535. In July 2021, the Japanese Ministry of Health, Labour and Welfare approved this antibody cocktail, now known by the trade name Ronapreve based on results from NCT04425629 (REGN-COV 2067) [3]. The UK's MHRA approved Ronapreve in August 2021 based on data from the RECOVERY trial (NCT04381936). |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04452318 | Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay | Phase 3 Interventional | Regeneron Pharmaceuticals | This study is evaluating a mixture of anti-spike protein mAbs REGN10933 (casirivimab) + REGN10987 (imdevimab). | |
| NCT04425629 | Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19 | Phase 2/Phase 3 Interventional | Regeneron Pharmaceuticals | ||
| NCT04381936 | Randomised Evaluation of COVID-19 Therapy | Phase 2/Phase 3 Interventional | University of Oxford | ||
